Welcome to NGC. Skip directly to: Search Box, Navigation, Content.


Brief Summary

GUIDELINE TITLE

Blepharitis.

BIBLIOGRAPHIC SOURCE(S)

  • American Academy of Ophthalmology Cornea/External Disease Panel, Preferred Practice Patterns Committee. Blepharitis. San Francisco (CA): American Academy of Ophthalmology (AAO); 2003. 17 p. [44 references]

GUIDELINE STATUS

This is the current release of the guideline.

This guideline updates a previous version: American Academy of Ophthalmology (AAO), Preferred Practice Patterns Committee, Cornea/External Disease Panel. Blepharitis. San Francisco (CA): American Academy of Ophthalmology (AAO); 1998. 16 p.

All Preferred Practice Patterns are reviewed by their parent panel annually or earlier if developments warrant.

BRIEF SUMMARY CONTENT

 
RECOMMENDATIONS
 EVIDENCE SUPPORTING THE RECOMMENDATIONS
 IDENTIFYING INFORMATION AND AVAILABILITY
 DISCLAIMER

 Go to the Complete Summary

RECOMMENDATIONS

MAJOR RECOMMENDATIONS

The ratings of importance to the care process (A, B, C) and the ratings for strength of evidence (I, II, III) are defined at the end of the "Major Recommendations" field.

Diagnosis

The initial evaluation of a patient with symptoms and signs suggestive of blepharitis should include the relevant aspects of the comprehensive medical eye evaluation. [A:III]

Patient History

Questions about the following elements of the patient history may elicit helpful information:

  • Symptoms and signs [A:III]
  • Duration of symptoms [A:III]
  • Unilateral or bilateral presentation [A:III]
  • Exacerbating conditions [A:III]
  • Symptoms related to systemic diseases [A:III]
  • Current and previous systemic and topical medications [A:III]
  • Recent exposure to an infected individual [C:III]

The ocular history may take into account details about previous eyelid and ophthalmic surgery and local trauma, including radiation and chemical trauma.

The medical history may take into account information about dermatological diseases such as acne, rosacea, and eczema, and about medications such as isotretinoin.

Examination

The physical examination includes measurement of visual acuity, [A:III] an external examination, [A:III] and slit-lamp biomicroscopy. [A:III] The external examination should be performed in a well-lighted room with particular attention to the following:

  • Skin [A:III]
  • Eyelids [A:III]

The slit-lamp biomicroscopy should include evaluation of the following:

  • Tear film [A:III]
  • Anterior eyelid margin [A:III]
  • Eyelashes [A:III]
  • Posterior eyelid margin [A:III]
  • Tarsal conjunctiva [A:III]
  • Bulbar conjunctiva [A:III]
  • Cornea [A:III]

Diagnostic Tests

A biopsy of the eyelid may be indicated to exclude the possibility of carcinoma in cases of marked asymmetry, resistance to therapy, or unifocal recurrent chalazion that do not respond well to therapy. [A:II] Consultation with the pathologist is recommended prior to obtaining a biopsy for suspected sebaceous gland carcinoma. [A:III]

Treatment

There is insufficient evidence to make definitive treatment recommendations for blepharitis. Treatments that are helpful include the following:

  • Warm compresses
  • Eyelid hygiene
  • Antibiotics
  • Topical corticosteroids

Patients should be advised that eyelid hygiene may be required for life, and that symptoms may recur if treatment is discontinued. [A:III]

For patients with staphylococcal blepharitis, a topical antibiotic such as bacitracin or erythromycin can be prescribed and applied on the eyelids one or more times daily or at bedtime for one or more weeks. The frequency and duration of treatment should be guided by the severity of the blepharitis. [A:III]

For patients with meibomian gland dysfunction (MGD), whose chronic symptoms and signs are not adequately controlled with eyelid hygiene, oral tetracyclines can be prescribed. [A:III] A brief course of topical corticosteroids may be helpful for eyelid or ocular surface inflammation such as severe conjunctival injection, marginal keratitis, or phlyctenules. If used, the minimal effective dose of corticosteroid should be utilized and long-term corticosteroid therapy should be avoided if possible. [A:III] Patients should be informed of the potential adverse effects of corticosteroid use, including the risk for developing increased intraocular pressure and cataract. [A:III] Guidelines for maintenance therapy should be discussed. [A:III]

Patients with atypical eyelid-margin inflammation or disease not responsive to medical therapy should be carefully re-evaluated. [A:III]

Follow-up

Patients with mild blepharitis should be informed to return to their ophthalmologist if their condition worsens. [A:III] Visit intervals for patients with severe disease are dictated by the severity of symptoms and signs, the current therapy, and comorbid factors, such as glaucoma, in patients treated with corticosteroids. The follow-up visit should consist of an interval history, measurement of visual acuity, external examination, and slit-lamp biomicroscopy. [A:III] If corticosteroid therapy is prescribed, patients should be re-evaluated within a few weeks to determine the response to therapy, measure intraocular pressure, and assess treatment compliance. [A:III]

Provider and Setting

The diagnosis and management of blepharitis requires broad medical skills and experience. Patients with blepharitis who are evaluated by non-ophthalmologist health care providers should be promptly referred to an ophthalmologist if any of the following occurs: [A:III]

  • Visual loss
  • Moderate or severe pain
  • Severe or chronic redness
  • Corneal involvement
  • Recurrent episodes
  • Lack of response to therapy

Counseling/Referral

One of the most important aspects of caring for patients with blepharitis is educating them about the chronicity and recurrence of the disease process. [A:III] Patients should be informed that symptoms can frequently be improved but are rarely eliminated. [A:III]

Definitions:

Ratings of importance to care process

Level A, most important
Level B, moderately important
Level C, relevant but not critical

Ratings of strength of evidence

  1. Level I includes evidence obtained from at least one properly conducted, well-designed randomized, controlled trial. It could include meta-analyses of randomized controlled trials.
  2. Level II includes evidence obtained from the following:
    • Well-designed controlled trials without randomization
    • Well-designed cohort or case-control analytic studies, preferably from more than one center
    • Multiple-time series with or without the intervention
  3. Level III includes evidence obtained from one of the following:
    • Descriptive studies
    • Case reports
    • Reports of expert committees/organization
    • Expert opinion (e.g., Preferred Practice Pattern panel consensus)

CLINICAL ALGORITHM(S)

None provided

EVIDENCE SUPPORTING THE RECOMMENDATIONS

TYPE OF EVIDENCE SUPPORTING THE RECOMMENDATIONS

The type of supporting evidence is identified and graded for each recommendation (see "Major Recommendations").

IDENTIFYING INFORMATION AND AVAILABILITY

BIBLIOGRAPHIC SOURCE(S)

  • American Academy of Ophthalmology Cornea/External Disease Panel, Preferred Practice Patterns Committee. Blepharitis. San Francisco (CA): American Academy of Ophthalmology (AAO); 2003. 17 p. [44 references]

ADAPTATION

Not applicable: The guideline was not adapted from another source.

DATE RELEASED

1998 Sep (revised 2003)

GUIDELINE DEVELOPER(S)

American Academy of Ophthalmology - Medical Specialty Society

SOURCE(S) OF FUNDING

American Academy of Ophthalmology

GUIDELINE COMMITTEE

Preferred Practice Patterns Committee, Corneal/External Disease Panel

COMPOSITION OF GROUP THAT AUTHORED THE GUIDELINE

Cornea/External Disease Panel Members: Alice Y. Matoba, MD (Chair); David J. Harris, Jr., MD; David M. Meisler, MD; Stephen C. Pflugfelder, MD; Christopher J. Rapuano, MD; Jayne S. Weiss, MD; David C. Musch, PhD, MPH (Methodologist)

Preferred Practice Patterns Committee Members: Joseph Caprioli, MD (Chair); J. Bronwyn Bateman, MD; Emily Y. Chew, MD; Douglas E. Gaasterland, MD; Sid Mandelbaum, MD; Samuel Masket, MD; Alice Y. Matoba, MD; Donald S. Fong, MD, MPH

FINANCIAL DISCLOSURES/CONFLICTS OF INTEREST

The following authors have received compensation within the past 3 years up to and including June 2003 for consulting services regarding the equipment, process, or product presented or competing equipment, process, or product presented:

Jayne S. Weiss, MD: Alcon, Allergan - Reimbursement of travel expenses for presentation at meetings or courses. Other authors have no financial interest in the equipment, process, or product presented or competing equipment, process, or product presented.

GUIDELINE STATUS

This is the current release of the guideline.

This guideline updates a previous version: American Academy of Ophthalmology (AAO), Preferred Practice Patterns Committee, Cornea/External Disease Panel. Blepharitis. San Francisco (CA): American Academy of Ophthalmology (AAO); 1998. 16 p.

All Preferred Practice Patterns are reviewed by their parent panel annually or earlier if developments warrant.

GUIDELINE AVAILABILITY

Electronic copies: Available from the American Academy of Ophthalmology (AAO) Web site.

Print copies: Available from American Academy of Ophthalmology, P.O. Box 7424, San Francisco, CA 94120-7424; Phone: (415) 561-8540.

AVAILABILITY OF COMPANION DOCUMENTS

PATIENT RESOURCES

None available

NGC STATUS

This NGC summary was completed by ECRI on February 20, 1999. The information was verified by the guideline developer on April 23, 1999. This summary was updated by ECRI on April 9, 2004. The information was verified by the guideline developer on May 20, 2004.

COPYRIGHT STATEMENT

This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions. Information about the content, ordering, and copyright permissions can be obtained by calling the American Academy of Ophthalmology at (415) 561-8500.

DISCLAIMER

NGC DISCLAIMER

The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.

All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.

Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at http://www.guideline.gov/about/inclusion.aspx .

NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding guideline content are directed to contact the guideline developer.


 

 

   
DHHS Logo